FEATURE: European VCs Grow Wary of Genomics | GenomeWeb

LONDON, Sept. 26 – For the past few years, European venture capital firms have been hustling to catch up with their American counterparts, establishing life science divisions and stepping up their investments in biotechnology companies.

Yet despite the enthusiasm for downstream companies promising novel medical technologies and treatments, European investors remain skittish about genomics and proteomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.